Siren L.L.C. Makes New Investment in Agenus Inc. $AGEN

Key Points

• Siren L.L.C. acquired a new stake in Agenus Inc. by purchasing 500,000 shares, valued at approximately $752,000, which represents about 1.82% ownership in the company.
• Agenus has received mixed ratings from analysts, with Zacks Research holding the stock at "hold" and HC Wainwright maintaining a "buy" rating with a target price of $23.00.
• The company reported a quarterly EPS of ($1.00), missing estimates, with revenues of $25.70 million, significantly below the expected $49.71 million.

Siren L.L.C. acquired a new stake in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 500,000 shares of the biotechnology company's stock, valued at approximately $752,000. Siren L.L.C. owned 1.82% of Agenus as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in AGEN. Corton Capital Inc. bought a new position in Agenus in the 4th quarter worth $36,000. Apollon Wealth Management LLC grew its holdings in shares of Agenus by 25.0% in the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 5,000 shares during the period. Invesco Ltd. bought a new position in Agenus in the first quarter worth approximately $88,000. Barclays PLC raised its holdings in Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock worth $90,000 after purchasing an additional 4,924 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Agenus by 32.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company's stock worth $96,000 after buying an additional 15,731 shares during the period. Institutional investors own 61.46% of the company's stock.

Wall Street Analyst Weigh In

AGEN has been the subject of several research reports. Wall Street Zen downgraded shares of Agenus from a "buy" rating to a "hold" rating in a report on Sunday, August 17th. Robert W. Baird raised their target price on shares of Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a report on Wednesday, June 4th. HC Wainwright restated a "buy" rating and issued a $23.00 target price on shares of Agenus in a report on Thursday, August 28th. Finally, Zacks Research upgraded shares of Agenus to a "hold" rating in a report on Tuesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Agenus has a consensus rating of "Moderate Buy" and an average price target of $14.50.

Agenus Price Performance

Shares of NASDAQ:AGEN traded up $0.15 during trading hours on Wednesday, hitting $4.31. The company's stock had a trading volume of 208,900 shares, compared to its average volume of 801,748. Agenus Inc. has a 52 week low of $1.38 and a 52 week high of $7.34. The company has a market capitalization of $137.32 million, a price-to-earnings ratio of -0.60 and a beta of 1.44. The firm's fifty day moving average price is $5.24 and its 200 day moving average price is $3.78.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million during the quarter, compared to the consensus estimate of $49.71 million. On average, equities research analysts predict that Agenus Inc. will post -12.55 earnings per share for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.